A practice with no medical indication supports a supply chain across two continents.
Between fifty and eighty percent of women in surveyed African communities practice some form of intravaginal cleansing, and the number holds across settings that share little else. A multicountry household survey conducted under World Health Organization coordination documented prevalence, method and motivation across sites in Africa and Asia, publishing in 2011 under a study group spanning Australian, Belgian, South African, Indonesian, Thai, Mozambican and Ugandan institutions. Practices ranged from washing with water to finger cleansing with soap to insertion of herbs, powders and antiseptics. What women reported wanting was hygiene, health, and the approval of male partners.
Commerce enters at motivation, which the survey recorded without editorializing. Women described cleansing as necessary after menstruation and after sex, as a requirement of cleanliness, and as a means of pleasing a partner who expected dryness or tightness. Products marketed into that demand address each stated motivation directly. Freshness answers odor. Tightening answers partner expectation. Drying answers the same. None of the three describes a clinical indication, and the third describes an outcome that reduces lubrication and increases mucosal trauma during intercourse.
Volume of trade is unrecorded anywhere this file could locate. No Nigerian customs category, no NAFDAC published figure and no industry association statistic captures how many units of intimate wash preparation enter or are manufactured in the country annually. Prevalence surveys establish that most women in surveyed communities practice some form of cleansing; nothing establishes what they are buying, from whom, or in what quantity.
Distribution across Nigeria follows the pattern the multicountry work recorded elsewhere. Practices cluster among younger women, among those with less formal education, and in communities where partner expectation is explicit. Supply follows demand into open markets, pharmacy shelves and online sellers, and the products reaching those channels include preparations manufactured locally, imported preparations, and repackaged antiseptics never formulated for mucosal application. Nothing in the distribution chain establishes what any given bottle contains.
Which evidence applies depends on how the practice is classified. The WHO study separated intravaginal cleansing from intravaginal insertion, and pooled analysis treats them separately for good reason: cleansing showed an association with HIV incidence at an adjusted hazard ratio of 1.88 with an interval spanning the null, while insertion of products for sex showed an unadjusted association that disappeared in the single adjusted estimate available. Reporting the two as one practice, which advocacy material regularly does, misstates both.
Plate 3.1 — What the Claim Promises
Products sold for intravaginal use, the motivation each addresses, and the clinical reality of each claim.
Evidence class: Documented — motivations and pooled findings as published
Method of application varies more than the product category suggests, and the variation determines exposure. Diary work among women in Uganda and Tanzania recorded practices daily across six weeks rather than relying on recall, capturing finger washing, cloth wiping and the insertion of water, soap, antiseptics and herbs. Recall-based surveys understate frequency, and a woman reporting that she cleanses after sex may be describing a daily event. Exposure assessment for any of these products has to begin from observed frequency, and almost none does.
Products themselves fall under the instrument this series has examined since Volume I. Feminine washes, gels and antiseptic preparations sold in Nigeria fall to NAFDAC, and the Medical Devices and Related Products (Registration, Labeling and Advertisement) Regulations, 2024 govern registration, labeling and advertisement of devices and related products. Regulation 20 requires a complete list of composition on the label in decreasing order of predominance, with any component known to cause hypersensitivity declared under subregulation seven.
Enumeration of the national register on 10 August 2026, reported in full in this series’ Greenbook special report, established what that register contains for menstrual products. Five records opened in full carried the product category rather than any chemistry in the field marked Composition. Three tampon products were registered under the category Sanitary Pads. Country of origin contradicted itself within individual records. A register in that condition cannot support a compliance check on any product class, and intimate wash preparations sit under the same instrument and the same registry practice.
A wash differs from a pad in one respect that raises the stakes considerably. A pad rests against keratinized skin, and Volume I established the barrier that provides. A wash is introduced into the vagina, against non-keratinized mucosa, in liquid form, under pressure, and Volume II established what that route does with anything crossing it. Surfactant, antiseptic, fragrance and preservative chemistry applied directly to that surface is the exposure scenario this series has spent two volumes establishing as the least characterized in the whole field.
Sellers online have widened the market beyond what any register tracks. Preparations promising tightening, whitening and drying circulate through social commerce channels where no registration number appears, and where the seller is frequently a reseller with no knowledge of the formulation. A product sold that way sits outside Regulation 20 in practice while remaining inside it in law, and neither the buyer nor the Agency can identify what is in the bottle.
Diagram 3.3 — Where a Wash Reaches
External cleansing and intravaginal introduction, and the tissue each one contacts.
Evidence class: Clinical schematic — documented tissue properties
Antiseptic preparations deserve separate mention because their mechanism is the problem. An antiseptic kills bacteria without discrimination, and the bacteria dominating a healthy vagina are the ones generating its protection. Applying a broad-spectrum agent to that community removes the protective organism along with anything else present, and the organism that recovers slowest is the acid producer. A product working exactly as designed produces the ecological outcome Part 1 described.
Nothing in the published literature measures it. No permeation coefficient exists for any component of any intimate wash across vaginal epithelium. No pharmacokinetic requirement attaches to these products, because they are not drugs. No ingredient disclosure obligation reaches them in most of the world, and where one exists, as in Nigeria, the register that would enforce it records nothing usable.
Dryness deserves its own paragraph, because it is sold as a benefit and functions as an injury. Products promising a dry or tight vagina reduce natural lubrication, and reduced lubrication during intercourse increases friction and mucosal microtrauma. Breaches in a non-keratinized surface are the entry route for the infections the same women are trying to avoid. A product cannot both deliver the dryness a partner expects and preserve the barrier that protects her, and no label acknowledges the trade.
Benefit can be assessed here rather than assumed, and the assessment is unambiguous. Systematic review of prospective studies concluded that intravaginal practices do not appear to protect women from vaginal infections. No specific vaginal practice showed a protective effect against HIV or against vaginal infections in that pooled analysis. Products sold on health claims into a market of tens of millions of African women address a condition they do not improve.
Diagram 3.2 — Same Instrument, Harder Exposure
How an intravaginal wash differs from an external pad under one Nigerian regulation, and what the register records.
Evidence class: Documented — statutory provision and register contents
Pricing tells its own story about who bears the risk. Intimate wash preparations retail across Nigerian markets at a fraction of a gynecological consultation, which makes self-treatment the rational response to a symptom for a woman weighing cost against a clinic queue. Discharge that signals bacterial vaginosis is treatable with a short course of metronidazole or clindamycin at modest cost, and reported cure rates within a month sit near seventy percent. Substituting a wash for that diagnosis converts a treatable infection into a recurring one.
Cultural objection is the serious one here and deserves full statement. Intravaginal practices carry meaning that a public health argument cannot dissolve by declaring them unnecessary, and cross-cultural work published in 2010 examined precisely this, situating vaginal practices within sexuality and relationship expectation rather than ignorance. Women practicing cleansing are responding to social conditions, including partner demand, that campaigns addressed only to them will not change. Beyond that, commercial soap and water cleansing of the external vulva is not douching, is not implicated in the same evidence, and conflating the two would tell women to abandon ordinary washing.
Both hold. Neither reaches the finding. External washing is not at issue anywhere in this part. What is at issue is a product category introduced into the vagina, marketed on claims of health and hygiene, demonstrated by pooled prospective evidence not to protect against the infections it claims to prevent, subject to a Nigerian labeling requirement that its register cannot enforce, and never assessed against the microbial community it displaces.
Right of reply extends to every manufacturer and distributor of intimate wash products sold in Nigerian markets and to NAFDAC as the registering authority. One question stands on the record: has any manufacturer of an intravaginal cleansing product sold in Africa tested that product’s effect on vaginal microbiota composition, and will those data be published? Replies to [email protected] will be published in full and unedited.
References
Sources are identified in the text by investigator and year wherever relied upon. A consolidated reference list in APA 7th edition, covering every source cited across all volumes and special reports of this series, will be compiled and published in the Consolidated Evidence Docket at series close. Verified entries to date are held in the production record of People & Polity Inc., New York.
